Mind the Gap: Pharma Chasing Biotech Assets

  • Recommend
  • Tweet
  • Print
  • Email

Validation with big pharma – is it still necessary? Depends on who you talk to. This was one of several questions posed to panelists at today’s business roundtable session. Arguments can be made on both sides, but one thing is for certain, the life sciences financing community has become much more sophisticated in recent years. And biotech and pharma companies have become more sophisticated in doing deals because they have a lot more experience to draw from. That’s definitely a win-win for everyone involved.